Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Bayer Health Care AG (study performed by Bayer Schering Pharma AG)

Femme et Homme Max 99 ans
Bayer Health Care AG (study performed by Bayer Schering Pharma AG) MAJ Il y a 4 ans

Estudio abierto, multicéntrico, en fase III, con lectura ciega de imágenes, para evaluar la eficacia y la seguridad de una única inyección intravenosa de 0,1 mmol / kg de peso corporal de gadobutrol 1,0 molar (Gadovist®) en pacientes con diagnóstico reciente de cáncer de mama referidos para resonancia magnética de mama, realzada con contraste An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 molar (Gadovist®) in patients with newly diagnosed breast cancer referred for contrast-enhanced breast MRI 1. La superioridad de la MRM combinada sin realzar y realzada con gadobutrol frente a la MRM sin realzar. 2. La superioridad de la MRM combinada sin realzar y realzada con gadobutrol más MRX frente a ...

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations

Femme et Homme Max 99 ans
Bayer Health Care AG (study performed by Bayer Schering Pharma AG) MAJ Il y a 4 ans

An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 molar (Gadovist®) in patients with newly diagnosed breast cancer referred for contrast-enhanced breast MRI The primary objectives of this study are to demonstrate: 1. Superiority of combined unenhanced and gadobutrol-enhanced MRM versus unenhanced MRM 2. Superiority of combined unenhanced and gadobutrol-en...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations